Iovance Biotherapeutics Inc

Iovance Biotherapeutics is a commercial-stage biotechnology company focused on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Its flagship product, Amtagvi (lifileucel), is the first FDA-approved, one-time TIL treatment for previously treated advanced melanoma, now approved in three global markets (U.S., Israel, and Australia) and available at more than 95 authorized treatment centers. Iovance also markets Proleukin, an interleukin-2 therapy used globally. The company operates as an end-to-end cell therapy company with fully owned, centralized U.S.-based manufacturing capable of serving thousands of cancer patients annually, with a manufacturing turnaround time of 31 days or less. Its clinical pipeline includes registrational programs in non-small-cell lung cancer (NSCLC), soft tissue sarcomas (UPS and DDLPS), frontline advanced melanoma, and serous endometrial cancer, along with next-generation programs featuring gene-edited TIL, IL-12 tethered TIL, and next-generation IL-2 therapies. The company owns or licenses more than 400 granted or allowed U.S. and international patents with exclusivity expected through at least 2042. Updated Aug 6, 2026